SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review.
Clicks: 84
ID: 281553
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
24.9
/100
84 views
24 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #100 of 111 articles by views in Frontiers in immunology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) typically lacks target-driven gene alterations and are primarily resistant to cytotoxic drugs. There is currently no standard treatment, especially for those who are unwilling or unable to receive chemotherapy. This case reported that chemotherapy-free strategy with tislelizumab and fruquintinib was utilized as a first-line treatment for a patient with SMARCA4-deficient NSCLC, and the patient achieved remarkable partial remission and lasted more than two years of disease control without severe adverse events.
| Reference Key |
dong2025smarca4deficient
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Dong, Jie; Zhang, Jinli; Pan, Hongming; Wang, Chongwei; Sheng, Jin |
| Journal | Frontiers in immunology |
| Year | 2025 |
| DOI |
10.3389/fimmu.2025.1521828
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.